

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

- | |
|--|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
| At scoping consultation, stakeholders identified that costs incurred by hospital visits and time off work to receive treatment will have a more significant impact on people with lower incomes. |
| Stakeholders also identified issues with variability of access to treatments at present due to ineligibility for autologous stem cell transplant and renal impairment, as well as worse outcomes for people with High Cytogenetic Risk Abnormalities (HCRA) and 1q21 amplification when treated with DRd (daratumumab, lenalidomide and dexamethasone). However, these highlighted issues do not relate to protected characteristics and are therefore not classed as potential equalities issues. |

- | |
|---|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
| Stakeholders further identified that transplant-eligible people currently benefit from quadruplet induction therapy with DVTd, but transplant-ineligible people do not. Access to IsaVRd therapy would help mitigate this inequality. |

But this also does not relate to protected characteristics and is therefore not classed as a potential equality issue.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

N/A

7. Have the committee's considerations of equality issues been described in the draft guidance, and, if so, where?

Yes, in section 3.16

Approved by Associate Director (name):Richard Diaz

Date: 20 May 2025